Pfizer Net Profit Margin 2010-2023 | PFE
Current and historical net profit margin for Pfizer (PFE) from 2010 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue. Pfizer net profit margin for the three months ending December 31, 2023 was .
| Pfizer Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2023-12-31 |
$58.50B |
$2.12B |
3.62% |
| 2023-09-30 |
$68.54B |
$10.48B |
15.29% |
| 2023-06-30 |
$77.94B |
$21.47B |
27.55% |
| 2023-03-31 |
$92.95B |
$29.05B |
31.25% |
| 2022-12-31 |
$100.33B |
$31.37B |
31.27% |
| 2022-09-30 |
$99.88B |
$29.77B |
29.81% |
| 2022-06-30 |
$101.28B |
$29.31B |
28.94% |
| 2022-03-31 |
$92.43B |
$24.97B |
27.01% |
| 2021-12-31 |
$81.29B |
$21.98B |
27.04% |
| 2021-09-30 |
$68.88B |
$19.43B |
28.21% |
| 2021-06-30 |
$55.12B |
$12.76B |
23.14% |
| 2021-03-31 |
$46.08B |
$10.68B |
23.18% |
| 2020-12-31 |
$41.65B |
$9.16B |
21.99% |
| 2020-09-30 |
$32.07B |
$7.73B |
24.10% |
| 2020-06-30 |
$34.47B |
$13.94B |
40.44% |
| 2020-03-31 |
$37.87B |
$15.50B |
40.92% |
| 2019-12-31 |
$40.91B |
$16.03B |
39.18% |
| 2019-09-30 |
$40.22B |
$16.22B |
40.32% |
| 2019-06-30 |
$40.84B |
$12.65B |
30.98% |
| 2019-03-31 |
$41.04B |
$11.48B |
27.97% |
| 2018-12-31 |
$40.83B |
$11.15B |
27.32% |
| 2018-09-30 |
$53.37B |
$23.82B |
44.63% |
| 2018-06-30 |
$53.24B |
$22.55B |
42.35% |
| 2018-03-31 |
$52.67B |
$21.75B |
41.29% |
| 2017-12-31 |
$52.55B |
$21.31B |
40.55% |
| 2017-09-30 |
$52.47B |
$9.81B |
18.69% |
| 2017-06-30 |
$52.35B |
$8.32B |
15.90% |
| 2017-03-31 |
$52.60B |
$7.30B |
13.88% |
| 2016-12-31 |
$52.82B |
$7.22B |
13.66% |
| 2016-09-30 |
$53.24B |
$6.27B |
11.77% |
| 2016-06-30 |
$52.29B |
$7.04B |
13.47% |
| 2016-03-31 |
$50.99B |
$7.62B |
14.95% |
| 2015-12-31 |
$48.85B |
$6.96B |
14.25% |
| 2015-09-30 |
$47.92B |
$8.36B |
17.45% |
| 2015-06-30 |
$48.20B |
$8.90B |
18.46% |
| 2015-03-31 |
$49.12B |
$9.18B |
18.69% |
| 2014-12-31 |
$49.61B |
$9.14B |
18.42% |
| 2014-09-30 |
$50.05B |
$10.48B |
20.93% |
| 2014-06-30 |
$50.33B |
$10.40B |
20.66% |
| 2014-03-31 |
$50.53B |
$21.58B |
42.71% |
| 2013-12-31 |
$51.58B |
$22.00B |
42.65% |
| 2013-09-30 |
$50.88B |
$25.75B |
50.61% |
| 2013-06-30 |
$51.19B |
$26.37B |
51.51% |
| 2013-03-31 |
$52.18B |
$15.53B |
29.75% |
| 2012-12-31 |
$54.66B |
$14.57B |
26.66% |
| 2012-09-30 |
$53.25B |
$9.69B |
18.21% |
| 2012-06-30 |
$56.90B |
$10.22B |
17.97% |
| 2012-03-31 |
$59.42B |
$9.58B |
16.12% |
| 2011-12-31 |
$61.04B |
$10.01B |
16.40% |
| 2011-09-30 |
$65.06B |
$11.46B |
17.62% |
| 2011-06-30 |
$64.44B |
$8.59B |
13.33% |
| 2011-03-31 |
$65.09B |
$8.45B |
12.99% |
| 2010-12-31 |
$65.17B |
$8.26B |
12.67% |
| 2010-09-30 |
$65.50B |
$6.13B |
9.36% |
| 2010-06-30 |
$61.13B |
$8.15B |
13.33% |
| 2010-03-31 |
$54.98B |
$7.93B |
14.43% |
| 2009-12-31 |
$49.27B |
$8.64B |
17.53% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$149.038B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
